1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904X2556</a>
Pages
1473–1481
Issue
9
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Current medical research and opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
*Levofloxacin; Administration; Adult; Anti-Bacterial Agents/*administration & dosage/economics; Bacterial/*drug therapy; Community-Acquired Infections/drug therapy; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions; Intravenous; Male; Ofloxacin/*administration & dosage/economics; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Milkovich Gary; Tennenberg Alan M; Xiang Jim X; Khashab Mohammed M; Zadeikis Neringa
Description
An account of the resource
OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. PATIENTS AND METHODS: A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. RESULTS: For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were comparable for the two regimens. CONCLUSIONS: The 750 mg levofloxacin dose resulted in a greater proportion of patients with resolution of CAP symptoms by Day 3 when compared with 500 mg therapy. Consequently, the 750 mg regimen trended toward more rapid transition to p.o., potentially resulting in lower overall drug costs. Time to switch from i.v. to p.o. was determined by the investigators' discretion rather than a set protocol. Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">10.1185/030079904X2556</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Levofloxacin
2004
Administration
Adult
Anti-Bacterial Agents/*administration & dosage/economics
Bacterial/*drug therapy
Community-Acquired Infections/drug therapy
Current medical research and opinion
Department of Internal Medicine
Drug Administration Schedule
Drug Costs
Female
File Thomas M Jr
Humans
Infusions
Intravenous
Khashab Mohammed M
Male
Milkovich Gary
NEOMED College of Medicine
Ofloxacin/*administration & dosage/economics
Oral
Pneumonia
Tennenberg Alan M
Treatment Outcome
Xiang Jim X
Zadeikis Neringa